126 studies found for:    PD-1
Show Display Options
Rank Status Study
21 Not yet recruiting Study of the Anti-PD-1 Antibody Nivolumab in Combination With Dabrafenib and/or Trametinib
Condition: Metastatic Melanoma
Interventions: Drug: Nivolumab;   Drug: Trametinib;   Drug: Dabrafenib
22 Recruiting A Phase II Study of Anti-PD-1 Antibody (MK-3475) in Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL) and Other Low Grade B Cell Non-Hodgkin Lymphoma
Conditions: Chronic Lymphocytic Leukemia;   Other Low-grade B-cell Non-Hodgkin Lymphomas
Intervention: Biological: Pembrolizumab
23 Recruiting A Dose Escalation and Cohort Expansion Study of Anti-CD27 (Varlilumab) and Anti-PD-1 (Nivolumab) in Advanced Refractory Solid Tumors
Conditions: Non-small Cell Lung Cancer;   Melanoma;   Malignant Melanoma of Head and Neck;   Ovarian Carcinoma;   Colon Cancer
Intervention: Drug: Combination of varlilumab and nivolumab
24 Recruiting Study to Evaluate the Effectiveness, Safety and Tolerability of Nivolumab in Subjects With Advanced Liver Cancer Anti-PD-1 HCC (Anti-Programmed-Death-1 Hepatocellular Carcinoma)
Condition: Hepatocellular Carcinoma
Intervention: Biological: Nivolumab
25 Withdrawn CT-011 and p53 Genetic Vaccine for Advanced Solid Tumors
Conditions: Breast Cancer;   Colon Cancer;   Pancreatic Cancer;   Sarcoma;   Ovarian Cancer
Interventions: Biological: p53: 264-272 peptide;   Drug: CT-011
26 Recruiting The Clinical Relevance of Immune Cells and CTC in HNSCC Patients
Conditions: Recurrence;   Metastasis;   Death
Intervention:
27 Recruiting Study of REGN2810 (Anti-PD-1) in Patients With Advanced Malignancies
Condition: Advanced Malignancies
Interventions: Drug: REGN2810;   Radiation: Hypofractionated radiotherapy;   Drug: Cyclophosphamide
28 Active, not recruiting Phenylbutyrate Response as a Biomarker for Alpha-synuclein Clearance From the Brain
Condition: Parkinson's Disease
Intervention: Drug: Glycerol Phenylbutyrate
29 Recruiting Alpha-synuclein in Cerebrospinal Fluid to Differentiate Alzheimer's Disease From Lewy Body Disease.
Condition: "Alzheimer's Disease" and "Lewy Body Disease"
Interventions: Other: MRI;   Procedure: lumbar puncture;   Behavioral: neuropsychological tests
30 Recruiting Anti-PD-1 Monoclonal Antibody in Advanced, Trastuzumab-resistant, HER2-positive Breast Cancer
Condition: Metastatic Breast Cancer
Intervention: Drug: MK-3475
31 Recruiting Anti PD1 Antibody in Diffuse Intrinsic Pontine Glioma and Relapsed Glioblastoma Multiforme
Condition: Malignant Gliomas
Intervention: Biological: CT-011
32 Recruiting MK-3475 and Gemcitabine in Non-Small Cell Lung Cancer (NSCLC)
Condition: Carcinoma, Non-Small-Cell Lung
Interventions: Drug: MK-3475;   Drug: Gemcitabine
33 Recruiting PH 1 Biomarker Study of Nivolumab and Ipilimumab and Nivolumab in Combination With Ipilimumab in Advanced Melanoma
Conditions: Advanced Melanoma;   Metastatic Melanoma
Interventions: Biological: Nivolumab;   Drug: Ipilimumab
34 Not yet recruiting A Combination Clinical Study of PLX3397 and Pembrolizumab To Treat Advanced Melanoma and Other Solid Tumors
Conditions: Melanoma;   Non-small Cell Lung Cancer;   Ovarian Cancer;   Triple-negative Breast Cancer;   Squamous Cell Carcinoma of the Head and Neck;   Bladder Cancer;   Pancreatic Ductal Adenocarcinoma;   Gastric Cancer
Interventions: Drug: PLX3397;   Biological: Pembrolizumab
35 Recruiting Biomarkers in Parkinsonian Syndromes
Conditions: Parkinsonian Syndromes;   Parkinson's Disease;   Multiple System Atrophy;   Progressive Supranuclear Palsy
Interventions: Other: CSF, blood and urine sampling;   Other: clinical measures of disease severity and progression
36 Recruiting Pembrolizumab in Treating Patients With Malignant Mesothelioma
Conditions: Biphasic Mesothelioma;   Epithelioid Mesothelioma;   Peritoneal Malignant Mesothelioma;   Pleural Biphasic Mesothelioma;   Pleural Epithelioid Mesothelioma;   Pleural Malignant Mesothelioma;   Pleural Sarcomatoid Mesothelioma;   Recurrent Peritoneal Malignant Mesothelioma;   Recurrent Pleural Malignant Mesothelioma;   Sarcomatoid Mesothelioma
Interventions: Biological: Pembrolizumab;   Other: Laboratory Biomarker Analysis;   Other: Pharmacogenomic Study
37 Recruiting Phase Ib and Phase II Studies of MK-3475 in Combination + for Renal Cell Carcinoma:
Condition: Clear Cell Renal Carcinoma
Interventions: Drug: MK-3475;   Drug: Bevacizumab
38 Recruiting Phase I/II Study of PDR001 in Patients With Advanced Malignancies
Conditions: Melanoma;   NSCLC;   Gastric Cancer;   Esophageal Adenocarcinoma;   Colorectal Cancer;   Anal Cancer;   Other Solid Tumors
Intervention: Biological: PDR001
39 Not yet recruiting Study of Pembrolizumab (MK-3475) Versus Placebo After Complete Resection of High-Risk Stage III Melanoma (MK-3475-054/KEYNOTE-054)
Condition: Melanoma
Interventions: Biological: pembrolizumab;   Other: placebo
40 Not yet recruiting Ph1b/2 Dose-Escalation Study of Entinostat With Pembrolizumab in NSCLC With Expansion Cohorts in NSCLC and Melanoma
Conditions: Non-Small Cell Lung Cancer;   Melanoma
Interventions: Drug: entinostat;   Drug: pembrolizumab

First Page    Show previous page of results Previous Page (1-20) Studies Shown (21-40) Next Page (41-60) Show next page of results    Last Page
Indicates status has not been verified in more than two years